CJC-1295 (No DAC) — Dosing, Cycles, Half-Life & Side Effects

CJC-1295 (No DAC) is a growth hormone releasing hormone (GHRH) analogue with a half-life of 30 minutes. Modified GHRH analog (also called Mod GRF 1-29) that stimulates pulsatile GH release from the pituitary. Provides physiological GH elevation without the sustained elevation of the DAC version. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassGrowth Hormone Releasing Hormone
Half-life30 minutes
HepatotoxicityNone
Suppression0/10

Typical Dosing Ranges

Common dose range: 100-200mcg 2-3x/day (often combined with GHRP)

Cycle length: 8-16 weeks

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Short half-life requires multiple daily doses
  • Best results when stacked with GHRP
  • Requires injection
  • Effectiveness varies between individuals

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of CJC-1295 (No DAC)?

CJC-1295 (No DAC) has a half-life of approximately 30 minutes. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for CJC-1295 (No DAC)?

Commonly reported ranges for CJC-1295 (No DAC): 100-200mcg 2-3x/day (often combined with GHRP). Cycle length: 8-16 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does CJC-1295 (No DAC) suppress natural testosterone?

CJC-1295 (No DAC) causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.

What is CJC-1295 (No DAC) typically used for?

CJC-1295 (No DAC) is commonly used for: Recovery enhancement, Anti-aging protocols, Body composition improvement, Sleep quality enhancement. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Is CJC-1295 (No DAC) legal?

CJC-1295 (No DAC) is a controlled substance in many jurisdictions (typically Schedule III in the US when it is an anabolic androgenic steroid). StackItSmart does not provide sourcing information. Possession, import, and use without a prescription carry legal consequences that vary by country and state.

Citations

  1. Teichman SL et al.. 2006. J Clin Endocrinol Metab — CJC-1295 DAC human PK; no dedicated human RCT for non-DAC variant
  2. Sigalos JT, Pastuszak AW. 2017. Sex Med Rev — Review of GH secretagogues: GHRH analogs (including CJC-1295 family) preserve pulsatile GH release with negative feedback intact; well tolerated but no rigorous long-term safety data
  3. Raun K et al.. 1998. Eur J Endocrinol — GHRH-receptor pharmacology and rationale for CJC-1295 + GHRP combination dosing pattern

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use CJC-1295 (No DAC). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content